Seeyond’s Regeneron Pharmaceuticals REGN Stock Holding History

Seeyond’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.95M	Buy	5,470 +873	+19%	+$644K	0.38%	67
2022 Q3	$3.17M	Sell	4,597 -573	-11%	-$361K	0.38%	58
2022 Q2	$3.06M	Sell	5,170 -1,921	-27%	-$1.25M	0.35%	68
2022 Q1	$4.95M	Sell	7,091 -2,667	-27%	-$1.69M	0.49%	28
2021 Q4	$6.16M	Sell	9,758 -1,846	-16%	-$1.13M	0.57%	23
2021 Q3	$7.02M	Sell	11,604 -1,416	-11%	-$879K	0.68%	17
2021 Q2	$7.27M	Buy	13,020 +33	+0.3%	+$16.7K	0.68%	18
2021 Q1	$6.14M	Buy	12,987 +6,624	+104%	+$3.23M	0.62%	24
2020 Q4	$3.07M	Buy	6,363 +2,717	+75%	+$1.47M	0.32%	56
2020 Q3	$2.04M	Sell	3,646 -292	-7%	-$177K	0.22%	122
2020 Q2	$2.46M	Buy	3,938 +284	+8%	+$161K	0.28%	77
2020 Q1	$89K	Buy	3,654 +669	+22%	+$276K	0.01%	579
2019 Q4	$1.12M	Sell	2,985 -1,724	-37%	-$580K	0.12%	308
2019 Q3	$1.31M	Sell	4,709 -1,080	-19%	-$320K	0.14%	258
2019 Q2	$1.81M	Sell	5,789 -194	-3%	-$64.6K	0.19%	190
2019 Q1	$2.46M	Buy	5,983 +3,201	+115%	+$1.32M	0.23%	133
2018 Q4	$1.04M	Buy	+2,782	New	+$1.02M	0.14%	225

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seeyond's REGN Position: Q4 2022 in Review

Seeyond increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q4 2022, buying an estimated $644K and bringing the position to 5,470 shares worth $3.95M. The position accounts for 0.38% of the portfolio, ranked #67.

Seeyond first reported a position in REGN in Q4 2018 and has held it in 17 quarters since. The position peaked at $7.27M in Q2 2021. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Seeyond held 5,470 shares of Regeneron Pharmaceuticals worth $3.95M as of Q4 2022.
Seeyond bought 873 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $644K.
Regeneron Pharmaceuticals made up 0.38% of Seeyond's portfolio in Q4 2022, its #67 holding.
Seeyond first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 17 quarters since.
Seeyond's Regeneron Pharmaceuticals position peaked at $7.27M in Q2 2021.
1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Seeyond's 13F filing for Q4 2022, filed 13 Feb 2023.